Introduction
============

Coronary artery disease is the leading cause of death globally,[@b1-tcrm-11-127] including in Thai-land.[@b2-tcrm-11-127] The association between elevated low-density lipoprotein cholesterol (LDL-C) and increased risk of coronary artery disease is well established.[@b3-tcrm-11-127],[@b4-tcrm-11-127] Acute coronary syndrome (ACS) is an important clinical manifestation of coronary artery disease[@b5-tcrm-11-127] and usually occurs as a result of one of three problems, ie, unstable angina, non-ST segment elevation myocardial infarction, or ST segment elevation myocardial infarction, which is diagnosed by electrocardiography. Patients with ACS are at very high risk of further life-threatening cardiac events, so intensive LDL-C-lowering therapy is needed soon after diagnosis.[@b3-tcrm-11-127],[@b4-tcrm-11-127],[@b6-tcrm-11-127]--[@b8-tcrm-11-127] Current guidelines therefore recommend more aggressive LDL-C targets for ACS patients compared with healthy patients (\<200 mg/dL or \<5.2 mmol/L) as per the updated National Cholesterol Education Program/Adult Treatment Panel III (NCEP/ATP III) guideline,[@b3-tcrm-11-127] and the guidelines of the European Society of Cardiology and the European Atherosclerosis Society (ESC/EAS)[@b9-tcrm-11-127] recommend an LDL-C goal of \<70 mg/dL (\<1.8 mmol/L).

The 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, also known as statins, are considered the first-line pharmacological therapy for reducing LDL-C levels to prevent progression of coronary artery disease.[@b3-tcrm-11-127],[@b9-tcrm-11-127],[@b10-tcrm-11-127] Six statins are currently available in Thailand, including simvastatin, pravastatin, fluvastatin, atorvastatin, rosuvastatin, and pitavastatin. Although all statins have a similar therapeutic effect (class effect) by lowering lipids, their potency differs.[@b11-tcrm-11-127] Combination therapy with statins and other lipid-lowering agents (eg, ezetimibe, bile acid resins, or niacin) is recommended to achieve optimal reduction in LDL-C and minimize the risk of adverse effects from statin use. In addition, statins are one of the top groups with regard to drug expenditure in Thailand. Not all statins are listed in the National List of Essential Medicines (NLEM), which is used by public health insurance schemes in Thailand as the reference for the pharmaceutical benefit package.[@b12-tcrm-11-127],[@b13-tcrm-11-127] About 96% of the Thai population are covered by one of three public insurance schemes: a civil servant medical benefit scheme for government officers and their dependants; a social security scheme for private sector employees; and universal coverage for people who are not eligible for either the civil servant medical benefit scheme or social security scheme.[@b12-tcrm-11-127] Thus, the NLEM influences physicians' choices of statins for LDL-C control in ACS patients.

Despite the current guidelines and efficacious lipid- lowering agents available, about half of very high-risk patients, including ACS patients, fail to achieve their LDL-C goal of \<70 mg/dL.[@b14-tcrm-11-127]--[@b25-tcrm-11-127] The highest success rate in achieving this goal came from a study in Hong Kong (83.1%),[@b26-tcrm-11-127] while the lowest reported success rate was in Greece (10%).[@b22-tcrm-11-127] However, studies of compliance with LDL-C levels of \<70 mg/dL in very high-risk patients, especially ACS patients, are limited in Asia, especially in Thailand. Two observational studies in Thailand have shown a low proportion of attainment of an LDL-C goal \<70 mg/dL in patients at very high risk for developing cardiovascular disease (Silaruks et al reported a rate of 11.6%[@b21-tcrm-11-127] and the CEPHEUS (CEntralized Pan-Asian survey on tHE Under-treatment of hypercholeSterolemia) Thailand survey reported 16.7%[@b17-tcrm-11-127]).

Little is known about the effects of statins of differing potency with regard to achieving a target LDL-C \<70 mg/dL in the real-world setting in Asia. This study investigated the success of ACS patients in achieving this goal, as well as any difference in effect of high potency statins versus low potency statins.

Materials and methods
=====================

Data source and data collection
-------------------------------

This retrospective cohort study was performed at the Maharaj Nakorn Chiang Mai Hospital in the north of Thailand. This tertiary hospital serves patients in Chiang Mai province, which has a population of 1,600,000, and receives patients with complicated conditions referred from 17 other provinces in northern Thailand. The hospital has 1,400 patient beds, and provides care for an average of 1,300,000 outpatients and 48,000 inpatients annually. This study was approved by the research ethics committee, Faculty of Medicine, Chiang Mai University, Thailand, before commencement, and included patients diagnosed with ACS between January 2009 and December 2011.

Data were collected by a study nurse aware of the research protocol and a researcher. Patient information, including demographic data, comorbidities, risk factors for coronary artery disease, current medication, and laboratory results including lipid profiles (total cholesterol, LDL-C, high-density lipoprotein, and triglycerides) were retrieved from medical charts and the electronic hospital database.

We retrospectively selected all patients aged 18 years and over who were diagnosed with an ICD-10 (International Statistical Classification of Diseases and Related Health Problems, Tenth Revision) code of I20 (angina pectoris) or I21 (acute myocardial infarction) who were treated with statins during admission or from the discharge date between January 2009 and December 2011. All included patients needed to have two assessments of their LDL-C levels and had to have remained on statin therapy between the two assessments, ie, one assessment at baseline during their hospital admission (index date) and one at follow-up within 2 weeks to 1 year following the index date. Patients with a baseline LDL-C \<70 mg/dL were excluded from the analysis ([Figure 1](#f1-tcrm-11-127){ref-type="fig"}).

Exposure and outcome measurement
--------------------------------

Patients were divided into two groups, as either high or low potency statin users. Patients in the high potency statin group were treated with simvastatin 40 mg, rosuvastatin 10 mg or 20 mg, atorvastatin 20 mg or 40 mg, or pitavastatin 2 mg daily which, based on previous studies, could be expected to achieve an LDL-C reduction of ≥40%.[@b11-tcrm-11-127],[@b27-tcrm-11-127],[@b28-tcrm-11-127] Patients on simvastatin 10 mg or 20 mg or pravastatin 40 mg daily were in the low potency statin group and had an expected LDL-C reduction \<40%.[@b11-tcrm-11-127],[@b27-tcrm-11-127],[@b28-tcrm-11-127]

The outcome target was achieving an LDL-C goal of less than 70 mg/dL (\<1.8 mmol/L) according to the updated NCEP/ATP III[@b3-tcrm-11-127],[@b10-tcrm-11-127] and ESC/EAS guidelines[@b9-tcrm-11-127] during the follow-up period of 2 weeks to 1 year.

Data analysis
-------------

Applying a descriptive method, counts and percentages were reported for categorical variables, and the mean and standard deviation for continuous variables. Differences between groups were compared using Fisher's Exact test for categorical variables or the independent *t*-test for continuous variables. Due to our use of an observational study design, which is prone to confounding factors, propensity scoring was used to adjust for confounding by indication.[@b29-tcrm-11-127]--[@b31-tcrm-11-127] Using logistic regression, a propensity score was generated to estimate the probability of receiving high or low potency statins. The variables included in the propensity score were age, sex, diabetes mellitus, hypertension, serum creatinine, alanine aminotransferase, LDL-C at baseline, health insurance status of patients, and smoking status. The Cox proportional hazard model (adjusted for propensity score and stratified by spectrum of ACS) was used to assess the effect of statin potency on LDL-C goal attainment. In all cases, the statistical significance level was set as two-tailed and at a *P*-value \<0.05. All statistical analyses were carried out using Stata version 12 software (StataCorp LP, College Station, TX, USA).

Results
=======

A total of 1,089 patients diagnosed with ACS were identified. After excluding 693 patients (627 with missing data on LDL-C levels, and 66 patients with a baseline LDL-C \<70 mg/dL), 396 patients were included in the final analysis ([Figure 1](#f1-tcrm-11-127){ref-type="fig"}). A comparison between the groups included and excluded from the final analysis showed no significant difference in demographics between the two groups, except that the included patients were younger than the excluded patients (64.4±11.9 years versus 67.8±12.7 years, respectively, *P*\<0.001).

Sixty percent of the patients were men, about 60% were covered by the universal coverage scheme, and one-fifth were current smokers. Fifty-five percent were diagnosed as having ST segment myocardial infarction, 28% as having non-ST segment myocardial infarction, and 16% as having unstable angina. The top three reported atherosclerotic risk factors were hypertension (60%), dyslipidemia (38%), and diabetes mellitus (28%). Two-fifths were treated with percutaneous coronary intervention during their hospital stay. The most frequently used current medications were antiplatelet/anticoagulant drugs (97%), beta-blockers (84%), and angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (65%, [Table 1](#t1-tcrm-11-127){ref-type="table"}). The baseline lipid profiles were 122.8±37.8 mg/dL for LDL-C, 40.3±11.1 mg/dL for high-density lipoprotein cholesterol, 143.4±79.1 mg/dL for triglycerides, and 191.5±46.3 mg/dL for total cholesterol ([Table 2](#t2-tcrm-11-127){ref-type="table"}). Simvastatin was the most commonly prescribed statin and statin monotherapy was predominantly used in this study ([Table 3](#t3-tcrm-11-127){ref-type="table"}).

Of the 396 ACS patients, 229 (57.8%) were treated with high potency statins and 167 (42.2%) with low potency statins. Both groups were similar with regard to demographic characteristics and risk factors for coronary artery disease. Patients covered by the universal coverage scheme were more often prescribed low potency statins, while those covered by the civil servant medical benefit scheme were more likely to receive high potency statins. Patients given high potency statins were more likely to have hypertension and dyslipidemia. Their pathology results and lipid profiles were similar, except that patients on high potency statins had higher total cholesterol and LDL-C levels at baseline ([Tables 1](#t1-tcrm-11-127){ref-type="table"} and [2](#t2-tcrm-11-127){ref-type="table"}). This suggests that the patients treated with high potency statins had more severe illness than those on low potency statins.

A quarter (24%) of the patients reached their target LDL-C, and there was no difference in LDL-C goal attainment between the high (24.9%) and low (23.4%) potency statin groups ([Figure 2](#f2-tcrm-11-127){ref-type="fig"}). The incidence rate of achieving the LDL-C goal was 2.0 per 1,000 person-days in patients with high potency statins and 1.7 per 1,000 person-days for those with low potency statins ([Table 4](#t4-tcrm-11-127){ref-type="table"}). Patients using high potency statins were no more likely to reach their LDL-C target than patients on low potency statins (hazards ratio 1.15, 95% confidence interval 0.76--1.73, *P*=0.516), and the results remained the same after adjusting for propensity score (adjusted hazards ratio 1.22, 95% confidence interval 0.79--1.88, *P*=0.363, [Table 5](#t5-tcrm-11-127){ref-type="table"}).

Discussion
==========

LDL-C goal attainment
---------------------

This clinic-based study in Thailand revealed that only a quarter of ACS patients (24%) attained their LDL-C goal of \<70 mg/dL. Although the success rate of ACS patients achieving this goal was higher than in previous studies in Thailand,[@b17-tcrm-11-127],[@b21-tcrm-11-127] most did not achieve their LDL-C target with the statin therapy available at the hospital. These results are consistent with other studies in Asian countries and worldwide, ie, that less than half of patients at very high risk for cardiovascular disease attain their LDL-C target, even though there are several efficacious lipid-lowering medications available.[@b14-tcrm-11-127]--[@b25-tcrm-11-127] Some studies have shown that less than 30% of high-risk patients reach their target LDL-C,[@b17-tcrm-11-127],[@b21-tcrm-11-127]--[@b24-tcrm-11-127],[@b32-tcrm-11-127],[@b33-tcrm-11-127] while other studies reported that target LDL-C was achieved by 30%--45% of patients at high risk of cardiovascular disease.[@b14-tcrm-11-127]--[@b16-tcrm-11-127],[@b18-tcrm-11-127]--[@b20-tcrm-11-127],[@b25-tcrm-11-127]

Inadequate statin therapy for lowering LDL-C might play a role in the failure of achieving target LDL-C. Most (98%) of the patients in our study used statin monotherapy, and simvastatin was the drug used most often, which is in line with other studies.[@b17-tcrm-11-127],[@b18-tcrm-11-127],[@b26-tcrm-11-127],[@b34-tcrm-11-127],[@b35-tcrm-11-127] According to the updated NCEP/ATP III and ESC/EAS guidelines, if the LDL-C goal is not achieved with statin monotherapy, combination therapy is recommended.[@b3-tcrm-11-127],[@b9-tcrm-11-127],[@b10-tcrm-11-127] Combination therapy that includes a statin plus another lipid-lowering agent (eg, ezetimibe, bile acid resins, or niacin) can achieve a considerable reduction in LDL-C levels, while also limiting the risk of dose-related adverse effects from statin therapy.[@b3-tcrm-11-127],[@b9-tcrm-11-127],[@b10-tcrm-11-127] Published studies have shown that the combination of a statin and ezetimibe is more effective than statin monotherapy in terms of lowering LDL-C and achieving the target of \<70 mg/dL.[@b36-tcrm-11-127]--[@b42-tcrm-11-127] Approximately 25% of patients in this study with LDL-C higher than 140 mg/dL at baseline would require combination therapy including a statin to achieve their target LDL-C. However, only seven patients (1.8%) were prescribed combination therapy. This is consistent with other studies reporting that statin combination therapy was used less frequently in routine practice.[@b18-tcrm-11-127],[@b35-tcrm-11-127],[@b39-tcrm-11-127],[@b42-tcrm-11-127] Although all treating physicians in this study were cardiologists, they were possibly reluctant to titrate statin doses upwards; there may be two reasons for this, ie, concern regarding potential adverse events, eg, an increase in muscle toxicity, and/or doubling the dose of a statin results in lowering LDL-C by only an additional 6%, ie, the "rule of 6".[@b43-tcrm-11-127],[@b44-tcrm-11-127]

The Thailand policy promoting the rational use of medicines may also play a role in the low rate of achievement of the LDL-C target. Thailand has adopted the NLEM to encourage rational drug use and to control drug cost in the country, so medicines listed in the NLEM can be prescribed for patients under the health insurance schemes, but patients have to pay for drugs not listed in the NLEM.[@b12-tcrm-11-127],[@b13-tcrm-11-127] Simvastatin was the only statin listed in the NLEM during the study period from 2009 to 2011.[@b45-tcrm-11-127] However, simvastatin 40 mg (the most commonly used high potency statin) can only reduce LDL-C by about 43%[@b46-tcrm-11-127] and cannot decrease the LDL-C level to \<70 mg/dL in patients with a level \>140 mg/dL at baseline. In this situation, atorvastatin, rosuvastatin or statin combination therapy should be used to lower LDL-C to the target level, but rosuvastatin and atorvastatin are not included in the NLEM. Our study suggests that physicians may have limited choices with regard to statin therapy for ACS patients, which impacts on LDL-C outcomes due to the regulations of the NLEM. A similar finding has been reported for Iceland, where a new reimbursement regulation was introduced in 2009 requiring patients to switch from atorvastatin, rosuvastatin, and pravastatin to simvastatin for the treatment of hyperlipidemia. After one year, the new reimbursement regulation resulted in an increase in cholesterol levels and decrease in the proportion of heart disease patients reaching the treatment goal.[@b47-tcrm-11-127]

Poor adherence to statin therapy might explain the failure to attain the LDL-C goal in this real-world practice study, given that adherence to statins is positively related to achieving the LDL-C goal.[@b48-tcrm-11-127]--[@b50-tcrm-11-127] Patients on statin therapy tend to decline in adherence after the initial prescription, and the 2-year adherence rate in ACS patients was reported to be only 40%.[@b51-tcrm-11-127] Patient adherence to statin therapy was not measured in this study, so further investigation of medication adherence in our population is warranted.

Effect of statin potency on LDL-C goal attainment
-------------------------------------------------

This study showed that treatment with a high potency statin was not associated with an increased likelihood of attaining the LDL-C goal in routine clinical practice. The effect of statin potency on reduction of LDL-C remains controversial in observational studies, although a positive relationship between statin potency and LDL-C goal attainment is well established in randomized controlled trials.[@b7-tcrm-11-127],[@b8-tcrm-11-127]

This study is in agreement with certain other studies showing that the potency of the statin used does not increase the likelihood of reaching the recommended goal.[@b15-tcrm-11-127],[@b18-tcrm-11-127],[@b35-tcrm-11-127],[@b52-tcrm-11-127] However, the results from yet other studies indicate that patients treated with high potency statins are significantly more likely to achieve LDL-C control.[@b22-tcrm-11-127],[@b32-tcrm-11-127],[@b53-tcrm-11-127],[@b54-tcrm-11-127] The difference in results between these carious studies might reflect differences in the definition of high or low potency of statins used in the studies, which could affect the percent of LDL-C reduction and lead to differences in successful goal attainment. For instance, a study by Rallidis et al[@b32-tcrm-11-127] showed a positive relationship between the potency of the statin and LDL-C control, and the definition of intensive lipid-lowering medication was a medication that could lower LDL-C by more than 50%. These drugs include rosuvastatin 20--40 mg, atorvastatin 40--80 mg, simvastatin 80 mg daily, and the combination of a statin at a moderate or high dose with ezetimibe, a bile acid sequestrant, or niacin. In our study, high potency statins were defined as simvastatin 40 mg, atorvastatin 20--40 mg, rosuvastatin 10--20 mg, and pitavastatin 2 mg daily, based on a percent LDL-C reduction of ≥40%.[@b11-tcrm-11-127],[@b27-tcrm-11-127],[@b28-tcrm-11-127] These treatment regimens fall mostly into the low to moderate potency category used in the study by Rallidis et al.[@b32-tcrm-11-127]

Other factors may have also influenced the results, such as comorbidities (particularly hypertension and dyslipidemia), individual variation in response to statin therapy, and variation in lifestyle and food modification. Patients on high-intensity statins had higher baseline LDL-C levels and a higher prevalence of hypertension and dyslipidemia, resulting in poorer LDL-C control. Individual patients may respond to statin therapy differently even at the same statin dose, resulting in different degrees of LDL-C reduction. Further, patients may differ significantly in their extent of lifestyle and food modification, which can also result in differing degrees of LDL-C reduction.

The timing of the follow-up visit may have influenced the results with regard to LDL-C goal attainment. A single follow-up visit between 2 weeks and 1 year after hospitalization for ACS was used in this study, whereas the follow-up duration in a study conducted in Europe and Canada was at least 3 months.[@b53-tcrm-11-127] We carried out a further analysis examining the relationship between statin potency and LDL-C goal attainment by varying follow-up duration (eg, 1 month, 2 months, 3 months, and 6 months), but the results remained the same. As mentioned earlier, the nonlinear decline in statin adherence after the initial prescription is a concern that could affect LDL-C goal attainment.[@b51-tcrm-11-127]

Further, high potency statins are recommended in the new 2013 American College of Cardiology/American Heart Association (ACC/AHA) guideline for the treatment of blood cholesterol to reduce the atherosclerotic cardiovascular risk in adults (ie, the 2013 ACC/AHA Cholesterol Guidelines)[@b55-tcrm-11-127] and lipid modification in the National Institute for Health and Care Excellence (NICE) clinical guideline 181,[@b56-tcrm-11-127] due to the results of randomized controlled trials considered by the guideline writers. Uncertainty appears to remain with regard to this policy. Our findings are at odds with the recommendations of the 2013 ACC/AHA Cholesterol Guidelines[@b55-tcrm-11-127] and the latest NICE guidelines from the UK,[@b56-tcrm-11-127] which no longer recommend use of both LDL-L goals and ongoing monitoring of LDL-C levels. Rather, our findings support the ESC/EAS[@b9-tcrm-11-127] and 2014 National Lipid Association[@b57-tcrm-11-127] recommendation that maintaining the LDL-C goal and monitoring of LDL-C levels are beneficial for physicians and patients in following the patient's progress. In this study, for example, monitoring of LDL-C was essential for identifying the 75% of patients who fail to achieve their LDL-C goal, and without monitoring, many ACS patients will be at increased risk of future cardiovascular events.

Strengths and limitations
-------------------------

To the best of our knowledge, this is the first study in Thailand that assesses the attainment of LDL-C \<70 mg/dL in those patients with ACS in routine clinical practice. Previous studies investigated reaching LDL-C \<100, or \<70 mg/dL in patients with cardiovascular risk. All patients were treated by a cardiologist. While previous studies in Thailand have had a cross-sectional design such that no causal relationship could be determined, our longitudinal study allows associations to be made.

This study has some limitations. First, its retrospective design may be distorted by confounding factors; however, we attempted to adjust for this by use of the propensity score to control for confounding. Second, inclusion of patients who had complete lipid profiles in their electronic medical records at both at baseline and follow-up resulted in fewer patients being included. However, a comparison between patients included and those excluded from the study found no significant difference. Third, the sample size in this study is too small for evaluation of the effect of statin potency on LDL-C goal attainment. However, it is still possible to legitimately establish an association between statin potency and LDL-C goal attainment in ACS patients. Fourth, these findings are limited in terms of their generalizability given that all patients were from a university affiliated hospital and all were managed by cardiologists. Therefore, our findings should not be generalized to ACS patients who were managed by primary care physicians or are from other parts of Thailand. Nonetheless, these findings are applicable in other Asian countries where physicians predominantly use statin monotherapy at low to medium potency in patients at high cardiovascular risk.[@b24-tcrm-11-127] Fifth, statin adherence and titration of the dose during treatment were beyond the scope of this study. If extremely low adherence is equally distributed between high and low potency statin users, our finding of no significant difference in LDL-C goal attainment between these two groups could be anticipated. There is a need for further assessment of medication adherence in statin users and the effect of statin dose adjustment to meet LCL-C goals in practice settings.

Conclusion
==========

Three-quarters of ACS patients failed to achieve their recommended LDL-C goal of \<70 mg/dL, and use of high potency statins was not associated with increased LDL-C control. We believe that this study reflects the real-world practice situation of suboptimal LDL-C goal achievement in ACS patients who are at high cardiovascular risk. Hence, we encourage cardiologists to use LDL-C goal attainment as a target for therapy, and to monitor LDL-C levels in ACS patients in order to prevent further cardiovascular events. Improvement in achieving the LDL-C goal is required in clinical practice to improve outcomes in ACS patients. Further studies are needed to identify the reasons for low LDL-C control rates. In addition, the impact of the NLEM on LDL-C control in very high-risk patients (eg, those with ACS) needing more intensive statin therapy requires further evaluation.
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###### 

Baseline characteristics of patients classified by statin potency (n=396)

  --------------------------------------------------------------------------------------------------------------
  Characteristics                                     High potency statins\   Low potency statins\   *P*-value
                                                      (n=229)                 (n=167)                
  --------------------------------------------------- ----------------------- ---------------------- -----------
  Sex                                                                                                

   Male to female                                     144 (62.9):85 (37.1)    92 (55.1):75 (44.9)    0.122

  Age (years)                                         63.9±12.0               64.8±11.0              0.453

  Health insurance                                                                                   

   Universal coverage scheme                          117 (51.1)              112 (67.1)             0.008

   Civil servant medical benefit scheme               99 (43.2)               49 (29.3)              

   Social security scheme                             11 (4.8)                4 (2.4)                

   Self-pay                                           2 (0.9)                 2 (1.2)                

  Smoking status                                                                                     

   Nonsmoker                                          143 (62.5)              92 (55.1)              0.315

   Ex-smoker                                          41 (17.9)               34 (20.4)              

   Current smoker                                     45 (19.7)               41 (24.6)              

  Diagnosis at discharge                                                                             

   Unstable angina                                    36 (15.7)               29 (17.4)              0.470

   NSTEMI                                             61 (26.6)               52 (31.1)              

   STEMI                                              132 (57.6)              86 (51.5)              

  Atherosclerotic risk factors                                                                       

   Diabetes mellitus                                  70 (30.6)               42 (25.2)              0.260

   Hypertension                                       151 (66.0)              89 (53.3)              0.013

   Chronic kidney disease                             26 (11.4)               24 (14.4)              0.444

   Dyslipidemia                                       97 (42.4)               52 (31.1)              0.027

   Family history of premature atherosclerosis        6 (2.6)                 1 (0.6)                0.247

  Previous history of cardiovascular events                                                          

   Chronic stable angina                              19 (8.3)                12 (7.2)               0.710

   Myocardial infarction or unstable angina           48 (21.0)               31 (18.6)              0.611

   Stroke (ischemic)                                  18 (7.9)                7 (4.2)                0.150

   Peripheral vascular disease                        1 (0.4)                 1 (0.6)                1.000

  Previous history of cardiovascular intervention                                                    

   PCI                                                15 (6.6)                8 (4.8)                0.520

   CABG                                               11 (4.8)                7 (4.2)                0.813

   Revascularization of peripheral vascular disease   2 (0.9)                 0 (0.0)                0.511

   Carotid intervention                               3 (1.3)                 0 (0.0)                0.267

  Treatment during admission                                                                         

   PCI                                                103 (45.0)              59 (35.3)              0.063

   CABG                                               2 (0.9)                 3 (1.8)                0.654

   Thrombolytic indicated                             26 (11.4)               22 (13.2)              0.641

  Current medications                                                                                

   Lipid-lowering drugs (non-statins)                 5 (2.2)                 2 (1.2)                0.704

   Antiplatelet/anticoagulant drugs                   223 (97.4)              164 (98.2)             0.739

   Beta-blockers                                      191 (83.4)              143 (85.6)             0.578

   ACEI/ARB                                           159 (69.4)              100 (59.9)             0.054

   CCB                                                40 (17.5)               34 (20.4)              0.515

   Diuretics                                          67 (29.3)               48 (28.7)              1.000
  --------------------------------------------------------------------------------------------------------------

**Note:** Numbers are n (%) or mean ± standard deviation (SD).

**Abbreviations:** NSTEMI, non-ST segment elevation myocardial infarction; STEMI, ST segment elevation myocardial infarction; PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting; ACEI/ARB, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers; CCB, calcium channel blockers.

###### 

Baseline laboratory and lipid values of patients by statin potency (n=396)

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------
  Characteristics                     High potency statins\                                   Low potency statins\                                    *P*-value
                                      (n=229)                                                 (n=167)                                                 
  ----------------------------------- ------------------------------------------------------- ------------------------------------------------------- -----------
  Baseline laboratory                                                                                                                                 

   Serum creatinine (mg/dL)           1.5±2.2                                                 1.3±0.7                                                 0.344

   ALT (U/L)                          31.6±38.7                                               34.9±30.4                                               0.356

   Fasting blood glucose (mg/dL)      132.1±50.5[a](#tfn4-tcrm-11-127){ref-type="table-fn"}   142.8±97.4[b](#tfn5-tcrm-11-127){ref-type="table-fn"}   0.164

  Baseline lipid values                                                                                                                               

   Total cholesterol (mg/dL)          195.1±45.4                                              186.8 ±47.2                                             0.089

   Triglycerides (mg/dL)              147.7±79.1                                              137.7±79.1                                              0.233

   High-density lipoprotein (mg/dL)   39.9±10.3                                               40.8±12.2                                               0.428

   Low-density lipoprotein (mg/dL)    127.1±38.6                                              116.8±35.9                                              0.007

  Propensity score                    0.61±0.13                                               0.54±0.13                                               \<0.001
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:** Numbers are mean ± standard deviation.

n=222,

n=161.

**Abbreviation:** ALT, alanine aminotransferase.

###### 

Statin therapy in this study (n=396)

  Statins (n, % of LDL-C reduction)   n (%)
  ----------------------------------- ------------
  High potency statins (229, ≥40)     
   Simvastatin 40 mg                  149 (65.1)
   Rosuvastatin 10 mg                 15 (6.6)
   Rosuvastatin 20 mg                 9 (3.9)
   Atorvastatin 20 mg                 33 (14.4)
   Atorvastatin 40 mg                 21 (9.2)
   Pitavastatin 2 mg                  2 (0.9)
  Low potency statins (167, \<40)     
   Simvastatin 10 mg                  11 (6.6)
   Simvastatin 20 mg                  155 (92.8)
   Pravastatin 40 mg                  1 (0.6)
  Monotherapy/combination therapy     
   Statin monotherapy                 389 (98.2)
   Statin combination therapy         7 (1.8)
    Statin + ezetimibe 10 mg          2
    Statin + gemfibrozil 300 mg       2
    Statin + gemfibrozil 900 mg       1
    Statin + fenofibrate cap 160 mg   1
    Statin + niacin 375 mg            1

**Abbreviation:** LDL-C, low-density lipoprotein cholesterol.

###### 

Incidence of LDL-C goal attainment by statin potency (n=396)

  -----------------------------------------------------------------------------------------------------
  Outcomes                                   High potency statins\   Low potency statins\   *P*-value
                                             (n=229)                 (n=167)                
  ------------------------------------------ ----------------------- ---------------------- -----------
  Total of person-days of follow-up          28,603                  22,551                 

  Median survival time (days)                298                     301                    

  LDL-C goal attainment (\<70 mg/dL)                                                        

   Number of patients with goal attainment   57                      39                     

   Incidence (per 1,000 person-days)         2.0                     1.7                    0.243
  -----------------------------------------------------------------------------------------------------

**Abbreviation:** LDL-C, low-density lipoprotein cholesterol.

###### 

Effect of statin potency on LDL-C goal attainment (n=396)

  Outcomes                             Crude HR (95% CI)[a](#tfn9-tcrm-11-127){ref-type="table-fn"}   *P*-value   Adjusted HR (95% CI)[a](#tfn9-tcrm-11-127){ref-type="table-fn"},[b](#tfn10-tcrm-11-127){ref-type="table-fn"}   *P*-value
  ------------------------------------ -------------------------------------------------------------- ----------- -------------------------------------------------------------------------------------------------------------- -----------
  LDL-C goal attainment (\<70 mg/dL)                                                                                                                                                                                             
   High potency statins                1.15 (0.76--1.73)                                              0.516       1.22 (0.79--1.88)                                                                                              0.363
   Low potency statins                 1.00                                                                       1.00                                                                                                           

**Notes:**

Stratified analysis by diagnosis at discharge.

Adjusted for propensity score including age, sex, diabetes mellitus, hypertension, serum creatinine, ALT, LDL-C at baseline, health insurance of patients, and smoking status.

**Abbreviations:** ALT, alanine aminotransferase; CI, confidence interval; HR, hazards ratio; LDL-C, low-density lipoprotein cholesterol.
